AZACITIDINE

Information current as at: 1 June 2026

PBAC meeting date: July 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Azacitidine Accord®

Azacitidine Dr Reddy’s®

Azacitidine Euglia® Azacitidine Juno® Azacitidine MSN® Azacitidine Sandoz®

Azacitidine SXP®
Form and strength:: Powder for injection 100 mg
Submission sponsor:: LICENSED STERILE COMPOUNDERS OF AUSTRALIA LIMITED
Condition/indication: (therapeutic use): Acute Myeloid Leukemia; Myelodysplastic syndrome; Chronic Myelomonocytic Leukemia
Listing requested:: To request that the listings for azacitdine transition to the Section 100 (Efficient Funding of Chemotherapy) program.
Funding program:: PBS Section 100 (Efficient funding of Chemotherapy)
Request authority level:: Authority Required
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: July 2026 PBAC meeting
Opportunity for consumer comment:: Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

1212

Page last updated

31 May 2026

v.9.19